Autogenous Veterinary Vaccines: What the Exemption Covers

Autogenous vaccines are made from the pathogens of a specific herd and used in that herd. Regulation (EU) 2019/6 allows them outside the marketing authorisation system, but only within narrow conditions and with some rules still applying.

What the Regulation says

Article 2(3) applies certain provisions to inactivated immunological veterinary medicinal products manufactured from pathogens and antigens obtained from an animal or animals in an epidemiological unit, and used for the treatment of those animals in the same unit or in a unit with a confirmed epidemiological link. The wording does not use the word autogenous, but this is the category it describes.

The conditions in practice

Guidance from Germany’s Paul-Ehrlich-Institut, which oversees immunologicals there, summarises the position. Such products do not need a marketing authorisation from the national authority or the European Commission, provided the conditions above are met. They may be marketed or used only in exceptional circumstances, where no authorised or registered immunological product is available for the purpose. They require a veterinary prescription, are subject to an advertising prohibition and must follow the principles of good manufacturing practice.

What stays outside the exemption

  • Live vaccines are not covered, because the provision refers to inactivated products.
  • Industrial use across unrelated farms falls outside the concept of an epidemiological unit or confirmed link.
  • Convenience is not a justification. If an authorised vaccine exists for the pathogen and species, the exemption does not support using an autogenous product instead.

National implementation

Details such as manufacturing licences, notification of production and reporting of pathogens, batches and quantities are set nationally. In Germany, for example, manufacturers notify the authority of their production, and the institute compiles annual data. Operators serving several Member States must therefore check each country’s rules, and should expect GMP guidance tailored to these products rather than the full industrial framework.

Points to document

  • The diagnostic isolate and the epidemiological unit it came from.
  • The reasoning showing that no authorised product could be used.
  • Manufacturing controls, batch records and traceability to the prescription.
  • Pharmacovigilance arrangements, including how suspected adverse events are passed on.

A risk-based approach for operators

Because the framework leaves much to national implementation, a risk-based quality approach is advisable even where a rule is not explicit. Operators should keep isolate records, manage cross-contamination between farm-specific batches and ensure that labelling identifies the unit and the prescription. Veterinarians who prescribe should also understand their duty to consider authorised alternatives first and to keep records that justify the choice.

  • Segregate batches by source unit at every step.
  • Keep a signed veterinary prescription with each supply.
  • Review the national position again before adding a new country.

How PQRA helps

PQRA can help manufacturers and veterinary service providers interpret the exemption, map national licensing and notification requirements, and build the documentation and quality arrangements that support a sound position.

Questions about this topic? Contact PQRA to discuss your veterinary portfolio.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *